Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $1,573,075.00 in Stock

Key Points

• Spyre Therapeutics CFO Scott Burrows sold 17,500 shares at an average price of $89.89, generating $1.57 million. The Rule 10b5-1 transaction reduced his holdings by 17.99%, leaving him with 79,762 shares.
• Spyre shares recently traded at $93.19, giving the company an $8.20 billion market capitalization. The stock has ranged from $15.86 to $110.18 over the past year, while its latest quarterly loss of $0.36 per share beat the $0.76 consensus estimate.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $109.71; institutional investors own approximately 80.39% of the company.

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 17,500 shares of the business's stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $89.89, for a total transaction of $1,573,075.00. Following the transaction, the chief financial officer owned 79,762 shares in the company, valued at $7,169,806.18. This trade represents a 17.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics Price Performance

Shares of NASDAQ:SYRE traded up $3.26 during trading hours on Friday, hitting $93.19. 1,235,015 shares of the company's stock traded hands, compared to its average volume of 1,229,962. The firm has a market capitalization of $8.20 billion, a P/E ratio of -47.79 and a beta of 3.10. The business has a fifty day moving average price of $95.71 and a 200-day moving average price of $81.43. Spyre Therapeutics, Inc. has a 1 year low of $15.86 and a 1 year high of $110.18.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.40. As a group, equities analysts predict that Spyre Therapeutics, Inc. will post -2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SYRE. Wells Fargo & Company lifted their target price on Spyre Therapeutics from $90.00 to $115.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. Robert W. Baird set a $120.00 price target on shares of Spyre Therapeutics in a research note on Wednesday, August 5th. JPMorgan Chase & Co. began coverage on shares of Spyre Therapeutics in a report on Thursday. They set an "overweight" rating and a $110.00 price objective for the company. Mizuho boosted their price objective on shares of Spyre Therapeutics from $84.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Finally, Wedbush restated an "outperform" rating and issued a $123.00 target price on shares of Spyre Therapeutics in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Spyre Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $109.71.

Institutional Investors Weigh In On Spyre Therapeutics

Several hedge funds have recently modified their holdings of the business. Integrated Wealth Concepts LLC bought a new position in shares of Spyre Therapeutics during the second quarter valued at approximately $31,000. Summit Securities Group LLC bought a new position in Spyre Therapeutics in the first quarter worth approximately $28,000. GAMMA Investing LLC lifted its holdings in Spyre Therapeutics by 26.8% during the second quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $59,000 after buying an additional 140 shares during the period. KBC Group NV purchased a new stake in Spyre Therapeutics during the first quarter worth $69,000. Finally, Nykredit A S bought a new stake in Spyre Therapeutics during the 2nd quarter valued at $173,000. Hedge funds and other institutional investors own 80.39% of the company's stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The company is working to create next-generation biologic medicines intended to address significant treatment needs in these chronic gastrointestinal conditions.

Spyre's pipeline includes programs directed at validated inflammatory pathways, including interleukin-23 (IL-23) and tumor necrosis factor-like ligand 1A (TL1A).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.